Project Grant 2136667
Award Date
3/1/22
Completion Date
2/28/23
Dollars Obligated
$256K
Federal Agency
Division of Industrial Innovation
Federal Grant Program
47.041
Assistance Type
Project Grant
Place of Performance
Boston, MA 02125, USA
Similar Awards
This $256,000 National Science Foundation project grant supports the generation of directly active monoclonal antibodies to CD19 for the treatment of B-cell malignancies by Welt Bio-Molecular Pharmaceutical, LLC. The grant funds research under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop novel monoclonal antibody therapies that could provide more affordable and less toxic options for leukemias and lymphomas compared to current drugs. Specifically, the awardee...
This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop a method to turn on cancer immunotherapies only at the site of disease. The $275,000 award will support Synsorybio, Inc., a for-profit organization, in creating protein switches that activate immunotherapies in response to disease signals, rather than indiscriminately throughout the body. This approach seeks to improve the...
This $255,730 National Science Foundation project grant supports the development of self-assembling molecular brachytherapy for treatment of metastatic cancer. The goal is to enable radiation therapies for metastatic cancer, which accounts for approximately 90% of cancer deaths in the United States each year. The grantee, Oncurie, LLC, seeks to advance a radiotherapy approach that exploits cancer cells themselves as catalysts for therapeutic delivery. Specifically, the company will develop an...
This Project Grant award of $305,000.00 from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program to Plexymer, Inc. in North Plainfield, NJ aims to develop an AI-driven platform to accelerate the bioformulation of antibody therapeutics. The project seeks to enable at-home self-administration of antibody medicines by pairing laboratory robotics with AI to rapidly identify stable, high-concentration formulations. This has the potential to...
This Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $305,000 to Absco Therapeutics, Inc. (doing business as Abscotx) to develop an image-guided intratumoral delivery system for administering immunotherapy biologics to treat solid tumors. The project aims to improve the localized retention, controlled release, and therapeutic efficacy of these biologics, addressing challenges with current intravenous and...
This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...
This $274,975 Small Business Innovation Research (SBIR) Phase I grant awarded by the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) supports the development of an antibody therapy targeting neoantigens in acute myeloid leukemia (AML). The project aims to create a platform technology that combines cancer-specific antibodies and adoptive natural killer (NK) immune cells to achieve high efficacy and low toxicity in treating relapsed/refractory AML. Key...
This $1,213,619 Cooperative Agreement awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program supports Encapsulate Inc., a small disadvantaged business, in developing a precision oncology platform that integrates microfluidics, biochips, bioreactors, and 3D tumor models. The goal is to create a rapid and accurate method for predicting the effectiveness of various cancer treatment options on individual patients, addressing a $2...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $303,864 to Core Biotherapeutics Inc. aims to develop a platform for disruptive drug candidates that can reprogram molecular networks to produce therapeutic effects beyond single-target approaches. The key objectives are to: 1) demonstrate that oligonucleotide drug efficacy is a function of transcription factor (TF) network reprogramming using a breast cancer cell line, 2) build a...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Covalabio Inc. supports the development of cell-penetrating monobodies as a new pharmaceutical intervention for treating certain cancers. The project aims to validate the cell-penetrating monobody technology by designing potent and selective inhibitors targeting oncogenic KRAS mutations in lung, pancreatic, and colorectal cancers. Key technical objectives include...